Xenon Pharmaceuticals Announces Publication of Results from XEN1101 Phase 2b " X-TOLE " Clinical Trial in Peer-Reviewed Journal Article in JAMA Neurology

VANCOUVER, British Columbia, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the medical journal JAMA Neurology has published peer-reviewed efficacy and...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials